In the study, which took place in mice, the new drugs reversed two major risk factors for cardiovascular disease—increased platelet responsiveness and excessive clot formation—by lowering levels of TMAO (trimethylamine N-oxide), a gut bacteria byproduct that forms during digestion.

https://m.medicalxpress.com/news/2018-08-potential-class-drugs-cardiovascular-gut.html